BetterLife’s Preclinical Studies Of BETR-001 For Depression Gets Additional Sponsorship By Mitacs
Biotech psychedelics company BetterLife Pharma Inc. (OTCQB: BETRF) in collaboration with the Carleton University Dept.
Field Trip Shares Fiscal Q4 And Full Year 2022 Results & Update On Court-Approved Corporate Reorganization
Psychedelic therapies developer and provider Field Trip Health Ltd.
Psychedelics Company Nabs Health Canada Construction Permit, Find Out How They Got It
Canadian life sciences company Nirvana Life Sciences Inc. (CSE: NIRV), focused on research & development of non-addictive pain management and relapse prevention products for pain and addictions, has been granted approval to build its R&D facility in Vancouver by Canada’s governmental department of Health.
HAVN Life Sciences & Optimi Health Corp Announce Supply Agreements, Here Are The Details
Two publicly traded psychedelics companies announced supply agreements. HAVN Life Sciences (OTC: HAVLF) will provide mental health clinic MPB Group Inc. with psilocybin-containing mushrooms for its therapeutic retreats in Jamaica and Optimi Health Corp.
Meet Alvaro Torres, CEO Of Lat Am & UK’s Top Medical Marijuana Brand At Benzinga’s Cannabis Capital Conference In September
After a prosperous Miami event this past April, the Benzinga Cannabis Capital Conference will take place in Chicago on September 13-14. As always, the meeting will host leading executives and investors who will talk about the industry’s present and future.
Cybin’s Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
Psychedelic biopharma company Cybin Inc. (NEO: CYBN) has received FDA Investigational New Drug Application (IND) approval for a Phase 1/2a clinical trial evaluating its proprietary CYB003 for treating major depressive disorder (MDD).
Biotech Company Pioneers Trademark Of MDMA Value Chain: Check Out The 2 Formats Available
Pharmala Biotech Holdings Inc. (CSE: MDMA), a company focused on research, development and manufacturing of MDMA and similar class molecules, has registered a trademark for its clinical-grade, Good Manufacturing Practice MDMA product, to be available as “Laneo MDMA.”
DMT Therapy Developer Small Pharma Posts Financial Results, Reaffirms Potential Of Short-Acting Psychedelics
Biotech company Small Pharma Inc. (OTCQB: DMTTF), producer of short-acting psychedelic-assisted therapies for diverse mental health conditions, announced its financial results earlier this month for the fiscal year ended Feb. 28, 2022.
Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), a biopharma company focused on progressing “psychedelics to therapeutics” through proprietary drug discovery platforms announced its financial and business results ended March 31, 2022.